Calcium is controlled by ryanodine receptors that lie inside cells and control the amount of calcium in the cell. But sometimes the receptors get stuck in the open position, allowing too much calcium to flow inside cells at an uncontrolled rate.
This leak of calcium was first discovered in heart failure but has also been linked to cognitive decline that accompanies heart failure, post-traumatic stress disorder, long COVID, and Alzheimer’s, based on findings from the lab of Andrew Marks, MD, chair and professor of physiology & cellular biophysics at VP&S and co-senior author of the new study.
Advertisement
When the NIH announced an initiative to fund research on the understudied phenomenon of chemotherapy-induced cognitive impairment, Marks and his collaborator, endocrinologist Theresa Guise, MD, of MD Anderson, decided to investigate whether calcium leaks could be responsible for this type of cognitive impairment as well.
The team tested the idea in mice and found that a chemotherapy treatment causes calcium leaks in the brain and neurocognitive dysfunction in mice with breast cancer and in healthy mice. The leaked calcium inside cells, the team found, impairs neuronal function.
The good news is that an experimental drug under development in the Marks lab was able to reduce both the calcium leak in the brain and neurocognitive symptoms in mice. Marks and his team hope that a clinical trial is soon to come, as there is currently no treatment for this common and distressing impairment.
The study also adds to the evidence that the calcium leak has an important role in cognitive deficits in general. “I think it’s a powerful story that we’ve converged on a similar pathway that affects cognition in multiple disorders and multiple settings,” Marks says.
Reference :
- Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice – (https://pubmed.ncbi.nlm.nih.gov/37756377/)
Source: Eurekalert
Source link
#Chemotherapy #Effect #Unlocks #Cognitive #Therapies
